5 Key Takeaways

• 1

  Liquid biopsy comprehensive genomic profiling (CGP) enhances precision oncology by providing earlier insights and faster access to targeted therapies.

• 2

  Liquid biopsy offers a non-invasive alternative to tissue testing, addressing limitations in obtaining sufficient tumor samples for genomic profiling.

• 3

  ctDNA analysis captures tumor heterogeneity and resistance mechanisms, providing a broader view than single tissue biopsies for treatment decisions.

• 4

  Integrating liquid biopsy into lung cancer pathways significantly reduces turnaround times for actionable results and accelerates treatment allocation.

• 5

  In breast cancer, ctDNA testing for ESR1 mutations demonstrates rapid results and the ability to detect low-frequency variants, aiding therapy guidance.